PIER MANNUCCIO MANNUCCI, M. D.; MASSIMO MORFINI, M.D.; LOREDANA GATTI, M.D.; DANIELA RAFANELLI, M.D.; MASSIMO COLOMBO, M.D.; DARIO GEROLDI, M.D.; MONICA EINARSSON, Ph.D.; ALESSANDRO R. ZANETTI, Ph.D.
Post-transfusion hepatitis is a serious and frequent complication in patients treated with clotting factor concentrates made from plasma pooled from a large number of donors. The occurrence is close to 100% in hemophiliacs who have not previously received blood or blood derivatives (first-exposure patients) (1-3). Recently, several manufacturers of concentrate have developed physical or chemical methods that remove or inactivate viruses with little or no loss of clotting factor activity. One manufacturer has added hydrophobic interaction chromatography on octanohydrazide-agarose to the regular fractionation process of a commercial concentrate of clotting factors II, VII, IX, and X (4). In-vitro studies have
MANNUCCI PM, MORFINI M, GATTI L, RAFANELLI D, COLOMBO M, GEROLDI D, et al. No Hepatitis After Treatment with a Modified Factor IX Concentrate in Previously Untreated Hemophiliacs. Ann Intern Med. ;103:226–227. doi: 10.7326/0003-4819-103-2-226
Download citation file:
Published: Ann Intern Med. 1985;103(2):226-227.
Gastroenterology/Hepatology, Liver Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use